Free Newsletter
ALSO NOTED: Ex-Chinese drug official gets 15 years;Sun gets FDA nod for generic dementia drug;
> A former Chinese drug regulator has been sentenced to 15 years in prison for bribery and embezzlement; the harsh punishment is seen as an example of the country's crackdown on food and drug safety. Report
> India's Sun Pharma got the FDA's blessing for its generic version of Exelon, an Alzheimer's and Parkinson's remedy made by Novartis--but won't launch the drug immediately because of outstanding patent litigation. Report
> GlaxoSmithKline has sold 2 million starter kits of its Alli weight-loss product in the five months since it was introduced; the results were in line with company expectations. Report
> A group of researchers are focused on developing a new, nonhormonal contraceptive that uses RNAi technology to silence the ZP3 gene, which is required to fertilize an egg during ovulation. Report
> A molecular mechanism at work during periods of stress may shed light on developing new therapies for post-traumatic stress disorder and other conditions. Report
And Finally... Americans love their sleeping pills, paying $4.5 billion for them annually. But patients think they work better than they really do. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: